-23%

est. 2Y upside i

HealthcareAI & MLSeries B

Leverage AI to generate protein candidates and improve their properties. More breakthroughs in fewer experiments — guided by your own experimental data.

Rank

#296

Sector

Biotechnology, AI/SaaS

Est. Liquidity

~4Y

Data Quality

Data: Low

Cradle presents a strong upside opportunity for a job seeker, driven by its robust AI-powered protein engineering platform and significant commercial traction with major pharmaceutical companies like Johnson & Johnson and Novo Nordisk.

Last updated: March 10, 2026

Bull (40%)+300%

Cradle significantly expands its customer base beyond the current 21, securing multiple new partnerships with top-tier pharmaceutical and industrial biotech companies, driven by its unique proprietary wet lab data and AI models. This leads to a rapid acceleration in revenue, potentially reaching $100M+ ARR by 2028, justifying a valuation of $1.4B or more at IPO or acquisition, representing a 4x return on current valuation.

Base (35%)+75%

Cradle continues its strong growth trajectory, expanding its existing partnerships and adding new clients at a steady pace. The platform becomes a standard tool for protein engineering in specific niches, driving ARR to approximately $55-60M by 2028. This growth supports a valuation of around $610M, offering a solid return on current equity.

Bear (25%)-60%

Increased competition from well-funded incumbents or new entrants, coupled with slower-than-expected adoption in the highly regulated biotech sector, limits Cradle's growth. Revenue stalls at around $35M ARR, leading to a down round or a lower-than-expected exit valuation of $140M. Given the significant liquidation preferences, common stock holders would see substantial losses.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Investors hold approximately $103M in liquidation preferences ahead of common stock, representing about 29.4% of the estimated $350M post-money valuation from the Series B round.

Dilution Risk

high

Given high capital intensity and being at Series B, further funding rounds are likely needed to reach profitability or exit, leading to additional dilution for existing equity holders.

Secondary Liquidity

none

There is no public information indicating active secondary markets or tender offers for Cradle's equity.

View all 13 open roles at Cradle →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Cradle's data — designed to show you've done your homework.

  • 1

    “With 6 of the top 25 pharma leaders as partners and a recent partnership with Bayer, how is Cradle thinking about scaling its commercial and customer success teams to manage these relationships and expand further into the vast TAM, particularly in the industrial biotech segment?”

  • 2

    “Cradle's model emphasizes customers retaining full IP. How does this strategy impact the long-term revenue potential and competitive positioning compared to companies that might seek royalty streams or co-development agreements?”

  • 3

    “Given the high capital intensity of biotech and the Series B funding, what is the company's anticipated timeline and strategy for future funding rounds or a potential liquidity event, and how might that impact employee equity?”

Community

Valuation Sentiment

Our model estimates -23% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.